Drug Approval | November 17, 2025
EMA recommends authorization of Teizeild to delay Type 1 diabetes onset
This is the first drug to receive a recommendation for this preventative indication in the European Union
This is the first drug to receive a recommendation for this preventative indication in the European Union
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Subscribe To Our Newsletter & Stay Updated
